Topiramate

• 

  Subject Areas on Research

  • A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients. 
  • Age, dose, and environmental temperature are risk factors for topiramate-related hyperthermia. 
  • Angle-closure glaucoma associated with ciliary body detachment in patients using topiramate. 
  • Assessment of interrater and intrarater reliability of the Fahn-Tolosa-Marin Tremor Rating Scale in essential tremor. 
  • Bilateral angle closure following use of a weight loss combination agent containing topiramate. 
  • Combination phentermine and topiramate extended release in the management of obesity. 
  • Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). 
  • Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. 
  • Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. 
  • Genetic and environmental correlates of topiramate-induced cognitive impairment. 
  • Health-related quality of life in two randomized controlled trials of phentermine/topiramate for obesity: What mediates improvement? 
  • Long-term patterns of weight changes during topiramate therapy: an observational study. 
  • Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. 
  • Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity. 
  • Potential genetic causes of heterogeneity of treatment effects. 
  • Potential neuroprotective effects of continuous topiramate therapy in the developing brain. 
  • The utility of the lh/lh mutant mouse as a animal model of human absence epilepsy. 
  • Topiramate for the prophylaxis of episodic migraine in adults. 
  • Topiramate in essential tremor: a double-blind, placebo-controlled trial. 
  • Topiramate monotherapy as broad-spectrum antiepileptic drug in a naturalistic clinical setting. 
  • Topiramate-induced confusion following a single ingestion of 400 mg. 
  • Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. 
  • Utility of the lethargic (lh/lh) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures. 
  • Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults.